NEW YORK (GenomeWeb News) – Exact Sciences today reported its revenues were flat for the second quarter year over year, while its net loss climbed sharply.

For the period ended June 30, the molecular diagnostics firm brought in revenues of $1 million, the same amount as it made during the quarter last year, matching Wall Street estimates.

All of the Madison, Wis.-based firm's revenues for the quarter were derived from license fees. It had no product royalty fees in the quarter compared to $6,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.